2024-10-24 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

**1. Performance Comparison with S&P 500 (VOO):**

Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of healthcare products, including pharmaceuticals, medical devices, nutritional products, and diagnostics. 

* **Cumulative return:** ABT (109.55) vs. VOO (136.39)
* **Relative Divergence:** -26.84 (15.18% relative to historical range)

ABT has underperformed the S&P 500 by -26.84% over the period analyzed.  While this is below the historical range, it suggests that ABT has not kept pace with the broader market. 

**2. Recent Price Movement:**

* **Closing price:** $117.04
* **5-day moving average:** $117.83
* **20-day moving average:** $115.12
* **60-day moving average:** $113.31

The stock is trading above its 5-day, 20-day, and 60-day moving averages, indicating a short-term bullish trend.

**3. Technical Indicators:**

* **RSI:** 62.46
* **PPO:** 0.18
* **Delta_Previous_Relative_Divergence:** 1.95 (Short-term upward trend)
* **Expected Return:** 0.0% (Long-term expected return relative to S&P 500)

The RSI suggests that ABT is in moderately overbought territory, while the positive PPO indicates upward momentum. The Delta_Previous_Relative_Divergence shows a recent short-term upward trend, but the expected return of 0% indicates that long-term returns may be in line with the S&P 500.

**4. Recent Earnings and Outlook:**

| Date        | EPS   | Revenue |
|--------------|-------|---------|
| 2024-07-31  | 0.74  | 10.38 B$ |
| 2024-05-02  | 0.7   | 9.96 B$ |
| 2023-11-01  | 0.82  | 10.14 B$ |
| 2023-08-03  | 0.79  | 9.98 B$ |
| 2024-07-31  | 0.79  | 9.98 B$ |

ABT has consistently reported stable earnings and revenue, though recent results have been slightly below analysts' expectations.  The most recent earnings report for Q2 2024 showed EPS of $0.74, which was below the consensus estimate of $0.82.  This suggests potential challenges for ABT in the near term.

**5. News and Recent Issues:**

Recent market outlook for ABT has been mixed.  Analysts are generally optimistic about ABT's long-term prospects, citing its strong brand recognition, diversified portfolio, and growth potential in emerging markets. However, there are some concerns about short-term growth due to the challenging macroeconomic environment.  

FINBOLD highlights that while ABT is experiencing a period of slowing revenue growth, the company is expected to benefit from long-term trends in the healthcare industry, such as the aging population and the growing demand for medical devices.  

**6. Summary:**

ABT is a stable, large-cap company with a diversified portfolio of healthcare products. However, the company has faced some challenges in recent quarters due to macroeconomic factors. While the stock has underperformed the S&P 500, technical indicators suggest a short-term upward trend. Long-term investors may find ABT attractive, but those seeking short-term gains may find other opportunities more promising.

**7. Overall, while Abbott Laboratories presents a solid investment option for long-term investors, current market challenges and recent underperformance relative to the S&P 500 suggest potential caution for short-term investors.**  
